Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2016-05-10 (9 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: ECOUFLANT (49000), Maine-et-Loire
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE D'ECOUFLANT : revenue, balance sheet and financial ratios
PHARMACIE D'ECOUFLANT is a French company
founded 9 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in ECOUFLANT (49000),
this company of category PME
shows in 2023 a revenue of 1.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE D'ECOUFLANT (SIREN 820188761)
Indicator
2025
2024
2023
2022
2021
2020
2019
2017
Revenue
N/C
N/C
1 534 944 €
N/C
N/C
N/C
N/C
N/C
Net income
112 771 €
91 113 €
113 503 €
127 704 €
121 409 €
108 464 €
73 582 €
40 305 €
EBITDA
N/C
N/C
168 002 €
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
7.4%
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE D'ECOUFLANT generates positive net income of 113 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 40 k€ -> 113 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
112 771 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 33%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 67%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
33.028%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
67.217%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2019
2020
2021
2022
2023
2024
2025
Debt ratio
1030.531
315.926
189.419
127.018
90.283
60.338
45.171
33.028
Financial autonomy
7.652
21.215
30.2
40.018
47.887
56.524
61.898
67.217
Repayment capacity
None
None
None
None
None
3.16
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
8.055%
None%
None%
Sector positioning
Debt ratio
33.032025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good-8 pts over 3 years
In 2025, the debt ratio of PHARMACIE D'ECOUFLANT (33.03) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
67.22%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good+8 pts over 3 years
In 2025, the financial autonomy of PHARMACIE D'ECOUFLANT (67.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
3.16 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of PHARMACIE D'ECOUFLANT (3.16) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 278.36. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
145.979
194.653
174.935
259.724
315.141
294.61
282.829
278.356
Interest coverage
None
None
None
None
None
4.638
None
None
Sector positioning
Liquidity ratio
278.362025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Excellent
In 2025, the liquidity ratio of PHARMACIE D'ECOUFLANT (278.36) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
4.64x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good
In 2023, the interest coverage of PHARMACIE D'ECOUFLANT (4.6x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE D'ECOUFLANT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
136 794 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
28
0
0
Customer payment term (days)
0
0
0
0
0
4
0
0
Supplier payment term (days)
0
0
0
0
0
27
0
0
Positioning of PHARMACIE D'ECOUFLANT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE D'ECOUFLANT is estimated at
1 791 380 €
(range 1 215 639€ - 2 810 923€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1215k€1791k€2810k€
1 791 380 €Range: 1 215 639€ - 2 810 923€
NAF 5 année 2025
Valuation method used
Net Income Multiple
112 771 €
×
15.9x
=1 791 381 €
Range: 1 215 639€ - 2 810 923€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE D'ECOUFLANT with other companies in the same sector:
Frequently asked questions about PHARMACIE D'ECOUFLANT
What is the revenue of PHARMACIE D'ECOUFLANT ?
The revenue of PHARMACIE D'ECOUFLANT in 2023 is 1.5 M€.
Is PHARMACIE D'ECOUFLANT profitable?
Yes, PHARMACIE D'ECOUFLANT generated a net profit of 113 k€ in 2025.
Where is the headquarters of PHARMACIE D'ECOUFLANT ?
The headquarters of PHARMACIE D'ECOUFLANT is located in ECOUFLANT (49000), in the department Maine-et-Loire.
Where to find the tax return of PHARMACIE D'ECOUFLANT ?
The tax return of PHARMACIE D'ECOUFLANT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE D'ECOUFLANT operate?
PHARMACIE D'ECOUFLANT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart